Sneddon-Wilkinson disease (SWD), also known as subcorneal pustular dermatosis, is a rare, chronic eruption characterized by annular, superficial, sterile pustules typically involving the intertriginous areas, trunk and proximal limbs.
1 SWD often affects middleaged women, may be associated with autoimmune disorders and is often difficult to treat. 1 To our knowledge, there are three case reports of antitumour necrosis factor-a (TNF-a) therapy with infliximab for SWD [2] [3] [4] and two case reports of etanercept for SWD. 5, 6 We report two patients whose SWD was refractory to numerous treatments before responding to etanercept 50 mg twice weekly (in combination with low-dose acitretin in one case).
Report
Patient 1 was a 51-year-old white man who presented with a 3-year history of a pruritic, pustular rash affecting the trunk, groin and limbs. The referring dermatologist had diagnosed subcorneal pustular dermatosis but the condition had been refractory to topical corticosteroids and acitretin 25 mg twice daily.
Physical examination revealed scaly, erythematous pustules, papules and plaques on the trunk, groin and proximal limbs covering 20% body surface area (BSA) (Fig. 1a) . Potassium hydroxide examination and fungal and bacterial cultures were negative. A punch biopsy was taken, and histological examination revealed a well-defined, sterile, subcorneal pustule with a superficial perivascular inflammatory infiltrate of lymphocytes and neutrophils and negative direct immunofluorescence, consistent with SWD ( Fig. 1b-d) .
Over the next 3 years, multiple treatments were attempted without benefit, including topical corticosteroids, pimecrolimus and tazarotene, narrowband ultraviolet (UV)B and oral cefdinir, tetracycline, dapsone, colchicine and methotrexate. No paraproteinaemia was found with serum protein electrophoresis. Etanercept 50 mg twice weekly was started as monotherapy. Three months later, the SWD was significantly improved (< 5% BSA). Eight months after starting etanercept, his SWD flared, involving 7% BSA. Acitretin was prescribed at a dose of 25 mg every other day. One month later, the SWD had nearly cleared and the patient was only taking 25 mg of acitretin twice weekly in addition to etanercept. The patient's SWD was virtually clear at last follow-up 13 months later (22 months after starting etanercept, maintained at 50 mg twice weekly).
Patient 2 was a 61-year-old African American man with a history of hypertension and coronary artery disease, who was referred with a history of several months of pruritic, erythematous and crusted papules and pustules on the chest, upper back and proximal thighs (approximately 10% BSA) (Fig. 2a) .
Biopsies taken by the referring dermatologist had shown intracorneal pustules with slight dermal inflammation with neutrophils and negative direct immunofluorescence, consistent with SWD ( Fig. 2b-d ). Multiple bacterial cultures were negative.
Over the next 3 years, multiple medications were attempted without benefit, including psoralen UVA, topical steroids, mupirocin, ketoconzole, salicylic acid and hydroquinone and tretinoin (for postinflammatory hyperpigmentation) and oral dapsone, colchicine, mycophenolate mofetil, antihistamines and short-courses of prednisone. No paraproteinaemia was detected on quantitative immunoglobulin measurements.
Etanercept 50 mg twice weekly was started as systemic monotherapy, with topical steroids as needed. At follow-up 1 and 4 months after starting treatment, he was markedly improved. At the 7-month follow-up, the SWD was slightly flaring but remained wellcontrolled with < 5% BSA involvement, and at the 9-month follow-up, it was markedly improved (Fig. 2e) . The patient noted that his SWD was better controlled on etanercept (maintained at 50 mg twice weekly) than any previous treatment. Many treatments for SWD have been reported, including dapsone, sulfapyridine, corticosteroids, retinoids, colchicine, ketoconazole, minocycline, ciclosporin, mebhydroline and phototherapy. 1 Although dapsone is often considered to be the first-line treatment, some patients fail to respond or cannot tolerate the sideeffects including haemolytic anaemia. In terms of antitumour necrosis factor (TNF)-a treatments, we are aware of only three reports of infliximab 2-4 and two reports of etanercept for SWD (Table 1) . 5, 6 The role of TNF-a in the pathogenesis of SWD is also supported by a case report 7 that showed increases in blister fluid and serum TNF-a levels in SWD. Furthermore, TNF-a plays an important role in the pathogenesis of inflammatory bowel diseases, pyoderma gangrenosum and rheumatoid arthritis, which have all been associated with SWD. Finally, some authors believe that SWD may evolve into or even be a variant of pustular psoriasis, consistent with a therapeutic role for anti-TNF-a treatments. 8, 9 Although combination therapy was used for patient 1, the patient had previously showed improvement with etanercept monotherapy for 8 months and has only required a minimal addition of acitretin (25 mg twice weekly) for the past 14 months. Our cases show that anti-TNF-a agents may be useful in treating SWD, in combination with other agents or possibly as monotherapy, particularly in patients who are unable to tolerate or are refractory to dapsone. 
